Now the organization is at a historic turning point, dealing with numerous lawsuits resulting from the acquisition of Monsanto, a pharmaceutical pipeline that is losing exclusivity, and a significant decline in market value over the past few years.

This has also sparked investor discussions about the possibility of splitting up the company. In this episode, CFO Wolfgang Nickl will discuss how he, along with the new CEO Bill Anderson and the rest of the Bayer team, are facing these challenges.

Hosts: Martin Glaum & Gori von Hirschhausen

Editorial Team: Simon Görlach & Marvin Schöne